The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Therapeutic insights for the aggressive subset of high-grade gliomas (HGG) driven by chromosome 1q32 MDM4-containing amplicon and unmethylated MGMT.
 
Wafik S. El-Deiry
Stock and Other Ownership Interests - Chimerix; Oncoceutics; p53-Therapeutics; SMURF-Therapeutics
Consulting or Advisory Role - Rain Therapeutics
Research Funding - Chimerix; D&D Pharmatech
Patents, Royalties, Other Intellectual Property - Patent on therapeutic targeting on hypoxia-inducible factors; Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53
Other Relationship - Caris Life Sciences
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences
 
Brooke Horowitch
No Relationships to Disclose
 
Emil Lou
Honoraria - Boston Scientific; Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline; Novocure
Consulting or Advisory Role - Boston Scientific; Novocure; Novocure; Novocure; Novocure
Research Funding - Intima; Novocure
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Minnetronix Medical; NomoCan
 
Vivek Subbiah
Consulting or Advisory Role - Bayer (Inst); Incyte (Inst); Loxo/Lilly; Novartis (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst)
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Relay Therapeutics (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Foundation Medicine; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Clinical Care Options; Medscape
 
Benedito A. Carneiro
Consulting or Advisory Role - Seagen
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Dragonfly Therapeutics (Inst); MiNK Therapeutics (Inst); Pfizer (Inst); Pyxis (Inst); Regeneron (Inst); Repare Therapeutics (Inst)
 
Howard Safran
No Relationships to Disclose
 
Ziya L. Gokaslan
No Relationships to Disclose
 
Robert W. Sobol
No Relationships to Disclose
 
Sendurai A. Mani
No Relationships to Disclose
 
Sean E. Lawler
No Relationships to Disclose
 
Clark C Chen
Consulting or Advisory Role - ClearPoint Neuro, Inc.; GTMedical; Monteris Medical
Speakers' Bureau - Varian Medical Systems
 
Eric T. Wong
Honoraria - Novocure; UpToDate; Zai Lab
Consulting or Advisory Role - Turning Point Therapeutics
Research Funding - Imvax (Inst); Novocure (Inst); Oblato (Inst); Orbus Therapeutics (Inst)
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Bicara Therapeutics; Biological Dynamics; Caris Life Sciences; Daiichi Sankyo; Datar Genomics; Eisai; EOM Pharmaceuticals; Gaido; Iylon; LabCorp; Loxo; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Precirix; Prosperdtx; Regeneron; Roche; Soluventis; TD2/Volastra; Turning Point Therapeutics; XBiotech
Speakers' Bureau - NeoGenomics Laboratories; Roche
Research Funding - Biological Dynamics (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); NCI (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - NCI SWOG; TargetCancer Foundation
 
Joanne Xiu
Employment - Caris Life Sciences
 
Andrew Elliott
Employment - Caris Life Sciences
 
Marzia Capelletti
No Relationships to Disclose
 
Steven Ressler
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Centers of Excellence
 
Ari M. Vanderwalde
Employment - Caris Life Sciences
Consulting or Advisory Role - George Clincal; West Clinic
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Replimune (Inst)
 
Chadi Nabhan
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
David Spetzler
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Caris Life Sciences
Research Funding - Caris Life Sciences
Patents, Royalties, Other Intellectual Property - Caris Life Sciences holds and has pending patents with intellectual property interests relating to health and medicine.
Travel, Accommodations, Expenses - Caris Life Sciences